ContraVir Pharmaceuticals Inc (NASDAQ:CTRV)‘s stock had its “buy” rating reiterated by equities research analysts at Noble Financial in a note issued to investors on Wednesday, AnalystRatings.NET reports. They currently have a $6.00 price objective on the stock. Noble Financial’s price target would indicate a potential upside of 244.83% from the stock’s previous close.
Shares of ContraVir Pharmaceuticals (NASDAQ:CTRV) traded down 10.2989% on Wednesday, hitting $1.5608. The company had a trading volume of 282,662 shares. The firm has a 50 day moving average of $1.04 and a 200-day moving average of $1.74. ContraVir Pharmaceuticals has a 12-month low of $0.76 and a 12-month high of $6.28. The firm’s market capitalization is $42.60 million.
ContraVir Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused primarily on the development of virology drugs to treat diseases of unmet needs, such as herpes zoster and hepatitis B (NASDAQ:CTRV). The Company is developing targeted antiviral therapies with two drug candidates in clinical studies.
